Document Detail


Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
MedLine Citation:
PMID:  20373246     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CHI's 17th International Tri-Conference on Molecular Medicine, held in San Francisco, included topics covering the drug discovery process, with an emphasis on lead optimization. This conference report highlights selected presentations on the development of several launched and investigational drugs, including Plerixafor, Trox-1 (CombinatoRX Inc), lorcaserin (Arena Pharmaceuticals Inc), vorapaxar (Merck & Co Inc) and ulimorelin (Tranzyme Pharma Inc).
Authors:
Graeme Semple
Related Documents :
12460856 - Careers of graduates of combined emergency medicine/internal medicine programs.
14530246 - Geriatrics training in general internal medicine fellowship programs: current practice,...
15209476 - Who does become an internist?
12950486 - American internal medicine in the 21st century: can an oslerian generalism survive?
11461206 - Managing workplace conflict in the united states and hong kong.
21783906 - Prioritizing veterinary pharmaceuticals for aquatic environment in korea.
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  IDrugs : the investigational drugs journal     Volume:  13     ISSN:  2040-3410     ISO Abbreviation:  IDrugs     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-07     Completed Date:  2010-09-14     Revised Date:  2010-12-20    
Medline Journal Info:
Nlm Unique ID:  100883655     Medline TA:  IDrugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  214-8     Citation Subset:  IM    
Affiliation:
Arena Pharmaceuticals, San Diego, CA 92127, USA. gsemple@arenapharm.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-HIV Agents / chemistry,  pharmacology,  therapeutic use
Benzazepines / chemistry,  pharmacology,  therapeutic use
Calcium Channel Blockers / chemistry,  pharmacology,  therapeutic use
Chemistry, Pharmaceutical*
Coronary Artery Disease / drug therapy
Drug Discovery / methods,  trends*
Heterocyclic Compounds / chemistry,  pharmacology,  therapeutic use
Humans
Ileus / drug therapy
Lactones / chemistry,  pharmacology,  therapeutic use
Macrocyclic Compounds / chemistry,  pharmacology,  therapeutic use
Obesity / drug therapy
Pyridines / chemistry,  pharmacology,  therapeutic use
Receptor, PAR-1 / antagonists & inhibitors
Receptors, CXCR4 / antagonists & inhibitors
Receptors, Ghrelin / agonists
Serotonin 5-HT2 Receptor Agonists
Serotonin Receptor Agonists / chemistry,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine; 0/Anti-HIV Agents; 0/Benzazepines; 0/CXCR4 protein, human; 0/Calcium Channel Blockers; 0/Heterocyclic Compounds; 0/Lactones; 0/Macrocyclic Compounds; 0/Pyridines; 0/Receptor, PAR-1; 0/Receptors, CXCR4; 0/Receptors, Ghrelin; 0/Serotonin 5-HT2 Receptor Agonists; 0/Serotonin Receptor Agonists; 0/TZP-101; 0/vorapaxar; 155148-31-5/JM 3100

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular Medicine - CHI's 17th International Tri-Conference - Mastering Medicinal Chemistry - CHI's...
Next Document:  HD Therapeutics - CHDI Fifth Annual Conference.